This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neurology  • Neuro-ophthalmology  • Ophthalmological Disorders, Other  • Alert me on articles by topic

Marc J. Dinkin, MD; Dean M. Cestari, MD; Marion C. Stein, MD; Steve D. Brass, MD; Simmons Lessell, MD

Arch Ophthalmol. 2008;126(4):566-570.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

When a laboratory test becomes available for a disorder previously diagnosed solely on clinical grounds, the spectrum of that disorder is apt to be expanded. With the discovery of a blood test (the NMO antibody) that has an estimated sensitivity of 76% and a specificity of 94%,¹ Devic disease is proving to be such an example. Devic recurrent neuromyelitis optica was considered a demyelinating disease in which the cardinal features were a bilateral optic neuropathy and a cervical myelopathy without other clinical or magnetic resonance imaging (MRI) evidence of involvement elsewhere in the nervous system and with a poor prognosis for recovery. With the advent of the NMO-antibody test, the picture of the syndrome is expanding.² We report on the cases of 3 women who suffered from recurrent optic neuritis (ON) . . . [Full Text of this Article]

Report of Cases

Case 1

Case 2

Case 3

Comment

AUTHOR INFORMATION